 | • レポートコード：TPM-NV181 • 出版社/出版日：Transparency Market Research / 2019年10月28日 • レポート形態：英文、PDF、193ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、慢性閉塞性肺疾患（COPD）治療の世界市場について調べ、慢性閉塞性肺疾患（COPD）治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別（併用療法、コルチコステロイド、ホスホジエステラーゼ4型阻害剤、ムコキネティクス、気管支拡張剤、その他）分析、流通チャンネル別（病院薬局、小売薬局、オンライン薬局）分析、関連企業情報などをまとめました。 ・慢性閉塞性肺疾患（COPD）治療の市場概要 ・慢性閉塞性肺疾患（COPD）治療の市場動向 ・慢性閉塞性肺疾患（COPD）治療の世界市場規模・予測 ・慢性閉塞性肺疾患（COPD）治療市場：薬物クラス別（併用療法、コルチコステロイド、ホスホジエステラーゼ4型阻害剤、ムコキネティクス、気管支拡張剤、その他） ・慢性閉塞性肺疾患（COPD）治療市場：流通チャンネル別（病院薬局、小売薬局、オンライン薬局） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
The chronic obstructive pulmonary disease treatment market is projected to be valued at ~US$ 26.2 billion in the year 2027. The high prevalence of chronic obstructive pulmonary disease (COPD) and the need for improved treatment options are catalyzing market growth.
To meet the needs of patients, healthcare companies in the COPD treatment market are developing efficacious treatment options in combination therapy. Revenue of combination therapy was valued at ~US$ 9.6 billion in 2018; the highest amongst all the drug classes in the chronic obstructive pulmonary disease treatment market.
With increased research & development, healthcare companies are innovating new triple combination therapies. For instance, in June 2019, AstraZeneca — an English-Swedish multinational pharmaceutical company, announced the approval of Breztri Aerosphere — a pressurized metered dose inhaler with built-in triple combination therapy for patients suffering from moderate to severe COPD in Japan. Stakeholders in the chronic obstructive pulmonary disease treatment market are running continuous clinical trials to meet the primary endpoints of the disease.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, 2017–2027
4.4.1. Market Revenue (US$ Mn) Projection
5. Market Outlook
5.1. Innovative Solutions for COPD Treatment
5.2. Pipeline Analysis
6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
6.3.1. Combination Therapy
6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
6.3.1.3. Triple Therapy
6.3.1.4. Others
6.3.2. Corticosteroids
6.3.3. Bronchodilators
6.3.3.1. Long Acting Beta Agonist (LABA)
6.3.3.2. Short Acting Beta Agonist (SABA)
6.3.3.3. Long Acting Muscarinic Antagonist (LAMA)
6.3.4. Phosphodiesterase Type 4 Inhibitors
6.3.5. Mucokinetics
6.3.6. Others
6.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Drug Class
7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Distribution Channel
8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by region
9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
9.2.1. Combination Therapy
9.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
9.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
9.2.1.3. Triple Therapy
9.2.1.4. Others
9.2.2. Corticosteroids
9.2.3. Bronchodilators
9.2.3.1. Long Acting Beta Agonist (LABA)
9.2.3.2. Short Acting Beta Agonist (SABA)
9.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
9.2.4. Phosphodiesterase Type 4 Inhibitors
9.2.5. Mucokinetics
9.2.6. Others
9.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country/Sub-region
10. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
10.2.1. Combination Therapy
10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
10.2.1.3. Triple Therapy
10.2.1.4. Others
10.2.2. Corticosteroids
10.2.3. Bronchodilators
10.2.3.1. Long Acting Beta Agonist (LABA)
10.2.3.2. Short Acting Beta Agonist (SABA)
10.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
10.2.4. Phosphodiesterase Type 4 Inhibitors
10.2.5. Mucokinetics
10.2.6. Others
10.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
11.2.1. Combination Therapy
11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
11.2.1.3. Triple Therapy
11.2.1.4. Others
11.2.2. Corticosteroids
11.2.3. Bronchodilators
11.2.3.1. Long Acting Beta Agonist (LABA)
11.2.3.2. Short Acting Beta Agonist (SABA)
11.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
11.2.4. Phosphodiesterase Type 4 Inhibitors
11.2.5. Mucokinetics
11.2.6. Others
11.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
12.2.1. Combination Therapy
12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
12.2.1.3. Triple Therapy
12.2.1.4. Others
12.2.2. Corticosteroids
12.2.3. Bronchodilators
12.2.3.1. Long Acting Beta Agonist (LABA)
12.2.3.2. Short Acting Beta Agonist (SABA)
12.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
12.2.4. Phosphodiesterase Type 4 Inhibitors
12.2.5. Mucokinetics
12.2.6. Others
12.3. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
13.2.1. Combination Therapy
13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
13.2.1.3. Triple Therapy
13.2.1.4. Others
13.2.2. Corticosteroids
13.2.3. Bronchodilators
13.2.3.1. Long Acting Beta Agonist (LABA)
13.2.3.2. Short Acting Beta Agonist (SABA)
13.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
13.2.4. Phosphodiesterase Type 4 Inhibitors
13.2.5. Mucokinetics
13.2.6. Others
13.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC
13.4.2. South Africa
13.4.3. Israel
13.4.4. Rest of Middle East & Africa
13.5. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share/ranking Analysis By Company (2018)
14.3. Company Profiles
14.3.1. AstraZeneca
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Boehringer Ingelheim International GmbH
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. GlaxoSmithKline plc
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Novartis AG
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. CHIESI Farmaceutici S.p.A.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Orion Corporation
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Mylan N.V.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis